Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors

/in , , , /by

PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]

Read more

Phase 1/2 Trial for AZD8359: a CD8-Biased T Cell Engager Targeting STEAP2 in m CRPC

/in , , , /by

Bispecific T cell engagers, while conceptually powerful, have carried a toxicity profile that constrains their clinical utility. AZD8359, a novel trispecific T cell engager now entering its first-in-human clinical trial, represents a thoughtful attempt to resolve that toxicity problem at the molecular engineering level, and its preclinical data are among the most compelling seen in this […]

Read more

Darolutamide Monotherapy in ARAMON Trial: 52-Week Results in Non-Metastatic or Oligometastatic CSPC

/in , , , , /by

A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]

Read more

PRINCE Trial Final Results: Lu-PSMA-617 + Pembrolizumab Shows Deep Responses in Advanced mCRPC

/in , , /by

The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]

Read more

UPDATE: MRT-2359 in Metastatic Castration-Resistant Prostate Cancer

/in , , /by

MRT‑2359 is an investigational, orally bioavailable molecular‑glue degrader targeting GSPT1, a protein involved in translation termination. We talked about this new molecule in this article just one month ago, we already have some good news. In prostate cancer it is being studied in combination with androgen‑receptor (AR)‑axis inhibitors, particularly in metastatic castration‑resistant prostate cancer (mCRPC), […]

Read more

Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial

/in , , /by

A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]

Read more

Phase 1/2 PARTHENON Trial: AZD4956 Targets HRD in Advanced Prostate Cancer

/in , , , /by

The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]

Read more

HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

/in , , , /by

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]

Read more

Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection

/in , , /by

64Cu-SAR-bisPSMA represents a next-generation PSMA-targeted PET imaging agent for prostate cancer, demonstrating superior lesion and patient detection in the Phase 2 Co-PSMA trial announced in February 2026. In this head-to-head study of 50 patients with biochemical recurrence (BCR) after prostatectomy (PSA 0.2-0.75 ng/mL), Cu-64 SAR-bisPSMA more than doubled mean lesions per patient at 1.26 (63 […]

Read more

Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC

/in , , , /by

Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. ​Eighty-four patients enrolled […]

Read more